Benzinga | Dec 9, 2021 09:46PM EST

RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates For H. pylori

RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication

Despite increasing resistance to, and suboptimal H. pylori eradication rates with, clarithromycin, a new study, published in Digestive Diseases and Sciences, indicates that over 80% of all prescriptions for H. pylori infection contain clarithromycin

In addition, this analysis highlighted a nearly 40% failure rate for clarithromycin-based triple therapies in treatment-na?ve patients; Study also showed a more than 80% failure rate in CYP2C19 rapid metabolizers, accounting for approximately 30% of Americans

Talicia, an FDA-approved therapy, is intended for first-line H. pylori eradication therapy